Skip to content
HowShorted

Emergent Biosolutions, Inc. short interest in 2022

In 2022, Emergent Biosolutions, Inc.'s disclosed short interest ran from 6.53% of shares outstanding on 14 Jan 2022 to 11.16% on 30 Dec 2022, a change of +4.63 percentage points. The year's high was 11.16% on 30 Dec 2022 and its low 3.91% on 31 Aug 2022, averaging 6.22% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.52 days on 15 Feb 2022. Full history: Emergent Biosolutions, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Emergent Biosolutions, Inc. in 2022

2022 in figures

Start of year
6.53% (14 Jan 2022)
End of year
11.16% (30 Dec 2022)
Change
+4.63 pp
High
11.16% (30 Dec 2022)
Low
3.91% (31 Aug 2022)
Average
6.22%
Highest days to cover
8.52 (15 Feb 2022)
SEC filings marked
9

Every report in 2022

Emergent Biosolutions, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20226.53%5.28results (8-K)
31 Jan 20226.87%6.45
15 Feb 20227.71%8.52
28 Feb 20227.33%6.24results (8-K), 10-K filed
15 Mar 20226.15%5.26
31 Mar 20225.63%5.18
14 Apr 20226.00%6.01
29 Apr 20227.28%6.00results (8-K), 10-Q filed
13 May 20226.65%4.21
31 May 20227.43%2.71
15 Jun 20226.69%5.57
30 Jun 20226.45%5.21
15 Jul 20226.85%6.94
29 Jul 20227.08%6.50
15 Aug 20226.00%3.45results (8-K), 10-Q filed
31 Aug 20223.91%3.35
15 Sep 20224.11%3.42
30 Sep 20224.48%3.37
14 Oct 20224.07%3.27
31 Oct 20224.32%3.29
15 Nov 20225.15%2.20results (8-K), 10-Q filed
30 Nov 20224.69%2.32
15 Dec 20226.84%3.57
30 Dec 202211.16%4.44

See also: Emergent Biosolutions, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.